SERF1A (small EDRK-rich factor 1A) is an intrinsically disordered protein localized to the nucleus and cytosol that functions as an RNA-organizing factor 1. However, its structural fuzziness—extreme conformational disorder even in bound states—paradoxically enables pathogenic interactions with amyloidogenic proteins. SERF1A promotes α-synuclein aggregation through multiple mechanisms: it partially deprotects amyloid nucleation elements in α-synuclein 2, facilitates cophase separation that converts toxic α-synuclein oligomers into less toxic fibrils 3, and accelerates amyloid-β fibrillization via charge-complementary interactions 4. The same N-terminal domain mediates these interactions and also drives huntingtin exon 1 fibrillization in Huntington's disease 5. SERF1A's inability to discriminate between RNA and amyloid proteins results from electrostatic binding through an identical positively charged site, causing toxic protein interactions to prevail under cellular stress 1. Clinically, SERF1A copy number variations modulate spinal muscular atrophy severity, with joint effects alongside SMN2 determining childhood-onset phenotype 6. SERF1A represents a novel therapeutic target for neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, and Huntington's disease by modulating amyloid aggregation pathways.